Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Defactinib

0a608fd7-c413-58d8-b186-9c2c29a1a208 · FDA Approved · targets FAK_PTK2

Defactinib

MeasuredReference

Defactinib targets ERBB4_HER4, FAK_PTK2, CLK1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

ERBB4_HER4FAK_PTK2CLK1CDK5_P25MLK3_MAP3K11

Top hallmarks

  • tumor promoting inflammation8.4k
  • proliferation7.1k
  • evading apoptosis6.8k

Top pathways disrupted

  • pi3k akt mtor signaling13.1k
  • apical junction11.8k
  • apoptosis11.8k

Resistance landscape — Defactinib

MeasuredReference

No variant annotations found on Defactinib's top targets.

No variant annotations on Defactinib's top targets.
Open in new tab